| Publications | PubMed=19920829; DOI=10.1038/sj.bjc.6605448; PMCID=PMC2813756
El-Sahwi K.S., Bellone S., Cocco E., Cargnelutti M., Casagrande F., Bellone M., Abu-Khalaf M., Buza N., Tavassoli F.A., Hui P., Silasi D.-A., Azodi M., Schwartz P.E., Rutherford T.J., Pecorelli S., Santin A.D.
In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.
Br. J. Cancer 102:134-143(2010) PubMed=21246534; DOI=10.1002/cncr.25891; PMCID=PMC3128671
Varughese J., Cocco E., Bellone S., de Leon M., Bellone M., Todeschini P., Schwartz P.E., Rutherford T.J., Pecorelli S., Santin A.D.
Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody.
Cancer 117:3163-3172(2011) PubMed=23891627; DOI=10.1016/j.ajog.2013.07.020
English D.P., Bellone S., Cocco E., Bortolomai I., Pecorelli S., Lopez S., Silasi D.-A., Schwartz P.E., Rutherford T.J., Santin A.D.
Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).
Am. J. Obstet. Gynecol. 209:465.e1-465.e9(2013) PubMed=26325104; DOI=10.1038/bjc.2015.306; PMCID=PMC4651122
Black J.D., Lopez S., Cocco E., Bellone S., Altwerger G., Schwab C.L., English D.P., Bonazzoli E., Predolini F., Ferrari F., Ratner E., Silasi D.-A., Azodi M., Schwartz P.E., Santin A.D.
PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.
Br. J. Cancer 113:1020-1026(2015) PubMed=26625219; DOI=10.1038/bjc.2015.388; PMCID=PMC4705897
Black J.D., Lopez S., Cocco E., Bellone S., Altwerger G., Schwab C.L., English D.P., Bonazzoli E., Predolini F., Ferrari F., Ratner E., Silasi D.-A., Azodi M., Schwartz P.E., Santin A.D.
Erratum to: PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.
Br. J. Cancer 113:1641-1641(2015) |
|---|
